Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Access to antiretroviral drugs and AIDS management in Senegal
AIDS, Volume 17, No. SUPPL. 3, Year 2003
Notification
URL copied to clipboard!
Description
Objectives: Description and analysis of the Senegalese Antiretroviral Drug Access Initiative (ISAARV), the first governmental highly active antiretroviral therapy (HAART) treatment programme in Africa, launched in 1998. Methods and results: ISAARV was initially an experimental project designed to evaluate the feasibility, efficacy and acceptability of HAART in an African context. It was based on four principles: collective definition of the strategy, with involvement of the health professionals who would be called on to execute the programme; matching the objectives to available means (gradual enrollment according to drug availability); monitoring by several research programmes; and ongoing adaptation of treatment and follow-up according to the latest international recommendations. Persons qualifying for antiretroviral (ARV) therapy are selected on the basis of immunological and clinical criteria, regardless of economic and social considerations. A system of subsidies was created to favor access to ARV. Following the ARV price reductions that occurred in November 2000, 100% subsidies were created for the poorest participants. Optimal adherence was ensured by monthly follow-up by pharmacists and support groups held by social workers and patient associations. The chosen supply and distribution system allowed drug dispensing to be strictly controlled. Conclusion: The ISAARV programme demonstrates that HAART can be successfully prescribed in Africa. This experience has served as the basis for the creation of a national treatment programme in Senegal planned to treat 7000 patients by 2006. © 2003 Lippincott Williams & Wilkins.
Authors & Co-Authors
Desclaux, Alice
France, Marseille
Aix Marseille Université
Ciss, Mounirou L.
Senegal, Dakar
Ministry of Health
Taverne, Bernard
Senegal, Dakar
Institut de Recherche Pour le Développement Dakar
Sow, Papa Salif
Senegal, Dakar
Fann University Hospital
Egrot, Marc
France, Marseille
Aix Marseille Université
Faye, Mame Awa
Senegal, Dakar
Fann University Hospital
Laniéce, Isabelle
Senegal, Dakar
National Aids Program
Sylla, Omar
Senegal, Dakar
National Aids Program
Delaporte, Éric
France, Montpellier
Université de Montpellier
Ndoye, Ibrahima
Senegal, Dakar
National Aids Program
Statistics
Citations: 62
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1097/00002030-200317003-00013
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cohort Study
Case-Control Study
Study Locations
Senegal